On Sunday, Johnson & Johnson (NYSE:JNJ) ) released updated results from an open-label, multicenter, multi-cohort Phase 1 study of TAR-210 in patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations. TAR-210 is an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib into the bladder. These data were featured at the 2024 American Urological Association (AUA) Annual Meeting. Results featured updated data from Cohort 1 (C1),
Real estate investor, Grant Cardone, issued a warning on May 5th regarding the stock market, posting on X: "WARNING: Stock Market is due for 50% correction taking S&P below 2674. Tens of millions of households will have their retirement & savings destroyed by being invested in stock market at these levels?" Cardone points to the history of the yield curve, which has been inverted for over 500 days. This scenario has occurred only three times since 1920—in 1929, 1974, and 2009. Following each of
The Florida Highway Patrol has confirmed a crash with injuries on the Dames Point Bridge heading south.